Antibody-Drug Conjugates: Global Clinical Trial Landscape (2024)

Don’t miss critical data and informative market analysis that examines ADC’s current state, development trends, and future potential.

This data-rich report features:

An introduction to ADC drugs
Current ADC clinical trial landscape
Drug development landscape for ADCs
An analysis of ADCs as leading innovations in oncology
Licensing, M&A, and venture funding landscape for ADCs
The important role of CMOs in ADC development
SWOT analysis of ADCs
An at-a-glance graphic of the key takeaways from the report

Read the Report

Your company email address

Please select your industry: (max 1)

Opt In?

Berne Media may store and process my information. For details, see the Privacy Notice.
Citeline (previously Pharma Intelligence UK) may contact me with updates, relevant promotions and information about products. My Information will be used in accordance with the Citeline Privacy Policy, and you withdraw your permission to receive any of our communications at any time.
By clicking submit, you consent to allow Novotech to store and process the information submitted to provide you the content requested. They are subject to Novotech’s Terms and Conditions.

Maximizing value across drug development: Embracing a new CDMO and CRO partnership approach

In this webinar, we will present key insights from preliminary findings by the TUFTS Center for the Study of Drug Development, exploring how a comprehensive model that brings CDMO and CRO services under one roof can significantly impact the expected Net Present Value (eNPV) of drug development programs. We will demonstrate how streamlined services across drug substance, drug product, and clinical research can enhance efficiency, reduce timelines, and ultimately deliver high-quality therapies to patients faster. Key takeaways include:

Antibody-Drug Conjugates: Global Clinical Trial Landscape (2024)

Read the Report

Opt In?

Explore similar content

Safety & Regulatory Compliance Predictions For 2025

Maximizing value across drug development: Embracing a new CDMO and CRO partnership approach

Getting The Most Out Of Your Lab Space